FT Options’s Alaunos Therapeutics TCRT Stock Holding History

FT Options’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-200	Closed	-$4K	–	355
2016 Q4	$4K	Sell	200 -723	-78%	-$652K	﹤0.01%	221
2016 Q3	$86K	Buy	923 +256	+38%	+$206K	0.07%	170
2016 Q2	$88K	Buy	+667	New	+$726K	0.08%	165

Other funds holding TCRT

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

FT Options's TCRT Position: Q1 2017 in Review

FT Options sold out of Alaunos Therapeutics (TCRT) in Q1 2017, closing a stake of 54 shares — an estimated $44K sold.

FT Options first reported a position in TCRT in Q2 2016 and held it in 3 quarters. The position peaked at $165K in Q2 2016. 124 funds tracked by Wall St. Rank hold TCRT as of Q1 2017.

FT Options reported no remaining Alaunos Therapeutics position as of Q1 2017 after selling out during the quarter.
FT Options sold 54 Alaunos Therapeutics shares in Q1 2017, an estimated $44K.
FT Options first reported a position in Alaunos Therapeutics in Q2 2016 and held it in 3 quarters.
FT Options's Alaunos Therapeutics position peaked at $165K in Q2 2016.
124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2017.

Based on FT Options's 13F filing for Q1 2017, filed 12 May 2017.